<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prolonged administration of <z:chebi fb="36" ids="29309">methyl</z:chebi> transferase inhibitors may increase response rates in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Fourteen <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with <z:hpo ids='HP_0001903'>anemia</z:hpo> and less than 10% marrow blasts received <z:chebi fb="0" ids="2038">azacitidine</z:chebi> 50 mg/m(2) thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin </plain></SENT>
<SENT sid="2" pm="."><plain>The response rate of 43% did not improve the rates reported with other <z:chebi fb="0" ids="2038">azacitidine</z:chebi> administration schedules, so the study was closed </plain></SENT>
<SENT sid="3" pm="."><plain>A <z:mp ids='MP_0006043'>decreased apoptosis</z:mp> of primitive erythroid progenitors and increased expression of BclX(L) was observed with treatment in responding patients compared to non-responders </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> may modulate BclX(L) and improve erythropoiesis through reduction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in primitive erythroid progenitor population in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>